BioSpace News Archive

Transcenta Holding Limited and Agilent Technologies, announce a collaboration to develop a Claudin18.2 companion diagnostic to support TranStar301 global Phase III pivotal trial of Osemitamab in combination with Nivolumab and chemotherapy as first-line treatment in patients with CLDN18.2 expressing locally advanced or metastatic gastric or gastroesophageal adenocarcinoma.

Mestag Therapeutics (“Mestag”), a biotech company harnessing new insights into fibroblast-immune interactions, is today presenting data on its M300 program in a late-breaking poster session at the 2024 American Association for Cancer Research (AACR) meeting.

Precision Neuroscience Corporation announced that Dr. Brian Otis has joined the company as Chief Technology Officer.

Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, announced the publication of two peer-reviewed research papers in Nature.

MiNK Therapeutics, Inc. (NASDAQ: INKT) today announced the presentation of data from MiNK-215, an investigational IL-15 armored fibroblast activation protein (FAP) targeting CAR-iNKT cell therapy, at the American Association for Cancer Research (AACR) Meeting in San Diego, CA.

Immunitas Therapeutics (“Immunitas”) today presented preclinical data supporting the combination potential of IMT-009 with anti-PD1 immunotherapy at the American Association for Cancer Research Annual Meeting (AACR 2024) in San Diego, California.

EpiBiologics, a preclinical stage company advancing new bispecific antibody therapeutics for extracellular protein degradation, is presenting data today on its EpiTAC protein degraders in oncology demonstrating robust in vivo anti-tumor activity and survival benefit.

Mythic Therapeutics, a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, presented preclinical data from MYTX-011, its investigational cMET-targeting ADC, at the American Association for Cancer Research (AACR) Annual Meeting.

MaaT Pharma (EURONEXT: MAAT – the “Company”) presented new in vitro data characterizing the metabolites produced by MaaT034 and their impact on immune modulation at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, California.

Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, today reported fourth quarter and full year 2023 financial results.